Correale, Pierpaolo <br/><br/>
Dose/dense metronomic chemotherapy with fractioned cisplatin and oral daily etoposide enhances the anti-angiogenic effects of bevacizumab and has strong antitumor activity in advanced non-small-cell-lung cancer patients.  [electronic resource] 

 -  Cancer biology & therapy  May 2010 
 - 685-93 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article 
<br/><br/><label>ISSN: </label>1555-8576 
<br/><br/><label>Standard No.: </label>10.4161/cbt.9.9.11441  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenocarcinoma--blood<br/>Administration, Oral<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Angiopoietin-1--blood<br/>Antibodies, Monoclonal--administration & dosage<br/>Antibodies, Monoclonal, Humanized<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Bevacizumab<br/>Carcinoma, Non-Small-Cell Lung--blood<br/>Carcinoma, Squamous Cell--blood<br/>Cisplatin--administration & dosage<br/>Drug Synergism<br/>Enzyme-Linked Immunosorbent Assay<br/>Etoposide--administration & dosage<br/>Female<br/>Humans<br/>Lung Neoplasms--blood<br/>Male<br/>Maximum Tolerated Dose<br/>Middle Aged<br/>Prospective Studies<br/>Survival Rate<br/>Thrombospondins--blood<br/>Treatment Outcome<br/>Vascular Endothelial Growth Factor A--blood